---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-041885"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:51:31.655602+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MangoRx Board initiates strategic alternatives review to maximize shareholder value

## Summary
- Formalized $150K promissory note with CEO's entity Cohen Enterprises at 8% interest, due Jan 2, 2025.
- Board formed strategy committee to explore mergers, acquisitions, divestitures, and business combinations.
- Process is in parallel with current operations; no timeline or assurance of any transaction.
- Company previously disclosed $50K loan from March 2024 and $100K loan from April 2024.

## SEC filing metadata
- accession: 0001493152-24-041885
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315224041885/0001493152-24-041885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315224041885/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-041885
- JSON: https://secwatch.observer/filing/0001493152-24-041885.json
- Plain text: https://secwatch.observer/filing/0001493152-24-041885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.